Author:
Pita Fernández Salvador,Pértega Díaz Sonia,López Calviño Beatriz,González Santamaría Paloma,Seoane Pillado Teresa,Arnal Monreal Francisco,Maciá Francesc,Sánchez Calavera María Antonia,Espí Macías Alejandro,Valladares Ayerbes Manuel,Pazos Alejandro,Reboredo López Margarita,González Saez Luis,Ramos Montserrat María,Segura Noguera Josep María,Monreal Aliaga Isabel,González Luján Luis,Martín Rabadán María,Murta Nascimento Cristiane,Pueyo Olga,Boscá Watts Marta Maia,Cabeza Irigoyen Elena,Casmitjana Abella Montserrat,Pinilla Marina,Costa Alcaraz Ana,Ruiz Torrejón Amador,Burón Pust Andrea,García Aranda Concepción,de Lluc Bennasar María,Lafita Mainz Sergio,Novella Maite,Manzano Hermini,Vadell Catalina,Falcó Esther,Esteva Magdalena
Abstract
Abstract
Background
Controversy exists with regard to the impact that the different components of diagnosis delay may have on the degree of invasion and prognosis in patients with colorectal cancer. The follow-up strategies after treatment also vary considerably. The aims of this study are: a) to determine if the symptoms-to-diagnosis interval and the treatment delay modify the survival of patients with colorectal cancer, and b) to determine if different follow-up strategies are associated with a higher survival rate.
Methods/Design
Multi-centre study with prospective follow-up in five regions in Spain (Galicia, Balearic Islands, Catalonia, Aragón and Valencia) during the period 2010-2012. Incident cases are included with anatomopathological confirmation of colorectal cancer (International Classification of Diseases 9th revision codes 153-154) that formed a part of a previous study (n = 953).
At the time of diagnosis, each patient was given a structured interview. Their clinical records will be reviewed during the follow-up period in order to obtain information on the explorations and tests carried out after treatment, and the progress of these patients.
Symptoms-to-diagnosis interval is defined as the time calculated from the diagnosis of cancer and the first symptoms attributed to cancer. Treatment delay is defined as the time elapsed between diagnosis and treatment. In non-metastatic patients treated with curative intention, information will be obtained during the follow-up period on consultations performed in the digestive, surgery and oncology departments, as well as the endoscopies, tumour markers and imaging procedures carried out.
Local recurrence, development of metastases in the follow-up, appearance of a new tumour and mortality will be included as outcome variables.
Actuarial survival analysis with Kaplan-Meier curves, Cox regression and competitive risk survival analysis will be performed.
Discussion
This study will make it possible to verify if the different components of delay have an impact on survival rate in colon cancer and rectal cancer. In consequence, this multi-centre study will be able to detect the variability present in the follow-up of patients with colorectal cancer, and if this variability modifies the prognosis. Ideally, this study could determine which follow-up strategies are associated with a better prognosis in colorectal cancer.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference37 articles.
1. Mortalidad por cáncer en España. 2007, [http://www.isciii.es/htdocs/pdf/mort2007.pdf]
2. Cabanes Domenech A, Pérez Gómez B, Aragonés N, Pollán M, López-Abente G: La situación del cáncer en España. 1975-2006. 2009, Madrid: Ministerio de Ciencia e Innovación
3. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I, Group E-W: Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007, 8 (9): 784-796. 10.1016/S1470-2045(07)70246-2.
4. Coleman M, Quaresma M, Berrino F, Lutz J, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, et al: Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008, 9 (8): 730-756. 10.1016/S1470-2045(08)70179-7.
5. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Lasota M, Coebergh J, Santaquilani M, group EW: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol. 2007, 8 (9): 773-783. 10.1016/S1470-2045(07)70245-0.